CalciMedica appoints Zaytsev to board, expands to eight directors

CalciMedica, Inc. disclosed in an 8-K dated July 2, 2026 that its board of directors increased the size of the board from seven directors to eight directors, on recommendation of the Nominating and Corporate Governance Committee.¹

The board appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director effective immediately, with a term expiring at the 2027 annual meeting of stockholders.¹ The filing states there are no arrangements or understandings between Dr. Zaytsev and any other person pursuant to which he was selected as a director, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.¹

Under the company's compensation policy for non-employee directors, Dr. Zaytsev will receive an annual cash retainer of $40,000, pro-rated based on days served, and was granted an option to purchase 20,000 shares of common stock, vesting monthly over three years from July 2, 2026, subject to continuous service.¹ He will also enter into the company's standard form of Indemnity Agreement for directors, previously filed as an exhibit to the company's 2020 Form S-1 registration statement.¹

Separately, Fred Middleton informed the board on July 2, 2026 of his intention to retire from the board effective at the company's 2026 annual meeting of stockholders.¹ Following his retirement, the board size will decrease back to seven directors.¹ The company said Middleton's retirement is not the result of any disagreement with the company on any matter relating to its operations, policies, practices or otherwise.¹

The filing was signed by CalciMedica Chief Executive Officer A. Rachel Leheny, Ph.D., and dated July 7, 2026.